In a significant advancement for the field of organ transplantation, the Microfluidics Innovation Hub (MIH) is proud to announce a pioneering collaboration with Accunea. This initiative marks a pivotal moment in our endeavor to push the boundaries of healthcare through the integration of innovative microfluidics technology.

In the ever-evolving field of microfluidics, FluIDect is leading the way with groundbreaking technology that is set to revolutionize microbial detection and quality control in industrial environments. This innovation leverages the capabilities of microfluidic technology to introduce a novel sensor system designed for continuous, real-time monitoring of liquid products for specific microbial presence.

Sensor chip production for a molecular recognition platform in medical diagnostics in general and for SARS-CoV-2 diagnostics (both antibody and viral genetic material testing) in particular.

AcouSome, an initiative by AcouSort, is set to change this by introducing an efficient, automated, and precise solution for exosome isolation.

Enzyre is revolutionizing personalized diagnostics with its groundbreaking chemiluminescent microfluidic platform, the EnzySystem. This innovative technology enables precise, near-patient testing of multiple coagulation markers from just a single drop of blood, transforming how bleeding disorders are managed and diagnosed.

VERAXA Biotech GmbH, renowned for their innovative HITMASTER platform, a groundbreaking microfluidic droplet-based screening system that revolutionizes functional antibody discovery.

BioAnalyt's iCheck Anemia project, developed in collaboration with the Microfluidics Innovation Hub, is creating a groundbreaking point-of-care diagnostic device for iron deficiency and anemia. This innovative microfluidic platform enables rapid, accurate, and user-friendly testing using a single drop of blood, revolutionizing early detection and treatment in both clinical and remote settings.

Cellsway’s microfluidic liquid biopsy platform, developed in collaboration with the Microfluidics Innovation Hub, enhances cancer diagnostics by enabling efficient separation and analysis of circulating tumor cells (CTCs) from blood samples. This

ViroGates, an international in vitro diagnostics company based in Denmark, is renowned for its innovative solutions in emergency medicine. Their suPARnostic® product line, used extensively in emergency departments, enhances clinical decisions regarding the hospitalization or discharge of acute medical patients.

Hycult Biotech, together with the Microfluidics Innovation Hub, is developing a rapid, non-invasive multiplex assay for detecting complement activation markers in chronic kidney disease. This advanced microfluidic platform aims to improve early diagnosis and monitoring, offering a reliable alternative to invasive kidney biopsies

MEPROlife's SpermSort technology revolutionizes sperm selection for assisted reproduction by combining advanced microfluidics with precise molecular diagnostics, significantly increasing pregnancy rates and improving IVF outcomes.